Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study

Table 4 Prescribed treatments for IPF management (including comorbidities) at 12 months according to baseline predicted FVC%

Prescribed treatments	Total	FVC < 50%	FVC 50–80%	FVC > 80%	P value
Total number of pharmacological treatments, n (%)^†	344 (100.0%)	53 (100.0%)	252 (100.0%)	39 (100.0%)	< 0.0001
Antifibrotic^a	201 (58.4%)	14 (26.4%)	160 (63.5%)	27 (69.2%)
Antacids^b	65 (18.9%)	5 (9.4%)	54 (21.4%)	6 (15.4%)
Systemic corticosteroids^c	23 (6.7%)	8 (15.1%)	15 (6.0%)	0 (0.0%)
Antibiotics for systemic use^d	15 (4.4%)	9 (17.0%)	4 (1.6%)	2 (5.1%)
Mucolytics^e	2 (0.6%)	0 (0.0%)	2 (0.8%)	0 (0.0%)
Anticoagulants^f	2 (0.6%)	1 (1.9%)	1 (0.4%)	0 (0.0%)
Other^g	36 (10.5%)	16 (30.2%)	16 (6.3%)	4 (10.3%)
Total number of non-pharmacological treatments, n (%)^‡	74 (100.0%)	27 (100.0%)	43 (100.0%)	4 (100.0%)	0.6688
Liquid oxygen therapy	13 (17.6%)	5 (18.5%)	7 (16.3%)	1 (25.0%)
Electric portable oxygen therapy	14 (18.9%)	5 (18.5%)	9 (20.9%)	0 (0.0%)
Oxygen therapy with oxygen concentrator	16 (21.6%)	6 (22.2%)	9 (20.9%)	1 (25.0%)
Oxygen therapy portable device	12 (16.2%)	2 (7.4%)	8 (18.6%)	2 (50.0%)
NIMV	3 (4.1%)	2 (7.4%)	1 (2.3%)	0 (0.0%)
Flu and pneumococcal vaccination	12 (16.2%)	4 (14.8%)	8 (18.6%)	0 (0.0%)
Nutritional supplements	2 (2.7%)	2 (7.4%)	0 (0.0%)	0 (0.0%)
Other^h	2 (2.7%)	1 (3.7%)	1 (2.3%)	0 (0.0%)

FVC forced vital capacity, ICU intensive care unit, IPF idiopathic pulmonary fibrosis, NIMV non-invasive mechanical ventilation, SD standard deviation
^aIncludes nintedanib (99 prescriptions, 49.3% of all antifibrotic treatments) and pirfenidone (102 prescriptions, 50.7% of all antifibrotic treatments)
^bIncludes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole and ranitidine
^cIncludes methylprednisolone and prednisone
^dIncludes azithromycin, levofloxacin, sulfamethoxazole plus trimethoprim, cefditoren, amoxicillin/clavulanic acid, ceftazidime, cefuroxime, and colistimethate sodium
^eIncludes acetylcysteine and carbocisteine
^fIncludes dabigatran etexilate and enoxaparin
^gIncludes antidiarrheal. anti-inflammatory /anti-infective intestinal agents, calcium. combinations with vitamin d and/or other drugs, immunosuppressants, alendronic acid, amlodipine, amphotericin B, bisoprolol, calcium carbonate, dexchlorpheniramine, dextromethorphan, fentanyl, folic acid, furosemide, indacaterol and glycopyrronium bromide, ipratropium bromide, isoniazide, loperamide in combination, metoclopramide, morphine, mycophenolic acid, tacrolimus, valganciclovir, among others
^hIncludes physiotherapy and other treatments
^†Over total number of pharmacological treatments prescribed in the total sample (n=344) and in each FVC% predicted group
^‡Over total number of non-pharmacological treatments prescribed in the total sample (n=74) and in each FVC% predicted group

ISSN: 1465-993X